| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A298380 Stock Overview
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
ABL Bio Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩21,450.00 |
| 52 Week High | ₩34,800.00 |
| 52 Week Low | ₩17,500.00 |
| Beta | 1.06 |
| 1 Month Change | -15.05% |
| 3 Month Change | -17.34% |
| 1 Year Change | 0.70% |
| 3 Year Change | -30.58% |
| 5 Year Change | n/a |
| Change since IPO | 57.14% |
Recent News & Updates
We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
We believe investing is smart because history shows that stock markets go higher in the long term. But not every stock...
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| A298380 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.4% | -2.8% | 0.006% |
| 1Y | 0.7% | -39.8% | -15.8% |
Return vs Industry: A298380 exceeded the KR Biotechs industry which returned -38.1% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned -15.2% over the past year.
Price Volatility
| A298380 volatility | |
|---|---|
| A298380 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in KR Market | 10.3% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A298380 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: A298380's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sang Hoon Lee | https://www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam, South Korea.
ABL Bio Fundamentals Summary
| A298380 fundamental statistics | |
|---|---|
| Market Cap | ₩1.02t |
| Earnings (TTM) | -₩43.56b |
| Revenue (TTM) | ₩5.33b |
191.6x
P/S Ratio-23.4x
P/E RatioIs A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298380 income statement (TTM) | |
|---|---|
| Revenue | ₩5.33b |
| Cost of Revenue | ₩47.98m |
| Gross Profit | ₩5.28b |
| Other Expenses | ₩48.84b |
| Earnings | -₩43.56b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -914.78 |
| Gross Margin | 99.10% |
| Net Profit Margin | -816.91% |
| Debt/Equity Ratio | 0% |
How did A298380 perform over the long term?
See historical performance and comparisonValuation
Is ABL Bio undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
18.25x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A298380's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A298380's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A298380 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.
PE vs Market: A298380 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A298380's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A298380 is overvalued based on its PB Ratio (18.3x) compared to the KR Biotechs industry average (3.3x).
Future Growth
How is ABL Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
13.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ABL Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has ABL Bio performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
35.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A298380 is currently unprofitable.
Growing Profit Margin: A298380 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: A298380 is unprofitable, but has reduced losses over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare A298380's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A298380 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).
Return on Equity
High ROE: A298380 has a negative Return on Equity (-77.85%), as it is currently unprofitable.
Financial Health
How is ABL Bio's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A298380's short term assets (₩45.5B) exceed its short term liabilities (₩8.8B).
Long Term Liabilities: A298380's short term assets (₩45.5B) exceed its long term liabilities (₩749.4M).
Debt to Equity History and Analysis
Debt Level: A298380 is debt free.
Reducing Debt: A298380 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A298380 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A298380 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.7% each year
Dividend
What is ABL Bio current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A298380's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A298380's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A298380's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A298380's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A298380 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.3yrs
Average management tenure
CEO
Sang Hoon Lee
6.33yrs
Tenure
Dr. Sang Hoon Lee, PH D co-founded PharmAbcine, Inc. in 2008 and serves as its Executive Vice President. Dr. Lee founded ABL Bio Inc. in February 2016 and serves as its President and Chief Executive Office...
Leadership Team
Experienced Management: A298380's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
ABL Bio Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: ABL Bio Inc.
- Ticker: A298380
- Exchange: KOSDAQ
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩1.021t
- Shares outstanding: 47.62m
- Website: https://www.ablbio.com
Location
- ABL Bio Inc.
- 16 Daewangpangyo-Ro 712 Beon-Gil
- 2nd Floor
- Seongnam-si
- Gyeonggi-do
- 13488
- South Korea
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/16 00:00 |
| End of Day Share Price | 2022/05/16 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.